CTI BioPharma Corp. (CTIC)

0.85
0.02 2.10
NASDAQ : Health Technology
Prev Close 0.87
Open 0.88
Day Low/High 0.85 / 0.88
52 Wk Low/High 0.60 / 2.30
Volume 67.06K
Avg Volume 251.60K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 48.73M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Interesting CTIC Put And Call Options For June 2016

Interesting CTIC Put And Call Options For June 2016

Investors in CTI BioPharma Corp saw new options become available this week, for the June 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Insider Trading Alert - CTIC, CRM And AXDX Traded By Insiders

Insider Trading Alert - CTIC, CRM And AXDX Traded By Insiders

Stocks with insider trader activity include CTIC, CRM and AXDX

Insider Trading Alert - RH, CTIC And SCOR Traded By Insiders

Insider Trading Alert - RH, CTIC And SCOR Traded By Insiders

Stocks with insider trader activity include RH, CTIC and SCOR

Insider Trading Alert - PFLT, CTIC And NSH Traded By Insiders

Insider Trading Alert - PFLT, CTIC And NSH Traded By Insiders

Stocks with insider trader activity include PFLT, CTIC and NSH

First Week of March 2016 Options Trading For CTI BioPharma (CTIC)

First Week of March 2016 Options Trading For CTI BioPharma (CTIC)

Investors in CTI BioPharma Corp saw new options become available this week, for the March 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Insider Trading Alert - ABM, CNBKA And CTIC Traded By Insiders

Insider Trading Alert - ABM, CNBKA And CTIC Traded By Insiders

Stocks with insider trader activity include ABM, CNBKA and CTIC

Interesting CTIC Put And Call Options For August 21st

Interesting CTIC Put And Call Options For August 21st

Investors in CTI BioPharma Corp saw new options begin trading this week, for the August 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new August 21st contracts and identified one put and one call contract of particular interest.

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

Strong On High Relative Volume: Cell Therapeutics (CTIC)

Strong On High Relative Volume: Cell Therapeutics (CTIC)

Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a strong on high relative volume candidate

Cell Therapeutics (CTIC) Is Today's Perilous Reversal Stock

Cell Therapeutics (CTIC) Is Today's Perilous Reversal Stock

Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a "perilous reversal" (up big yesterday but down big today) candidate

Strong On High Volume: Cell Therapeutics (CTIC)

Strong On High Volume: Cell Therapeutics (CTIC)

Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a strong on high relative volume candidate

ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab

ASCO '15 Report Card: Grading Biotech and Drug Stocks at Cancer Drug Confab

The ASCO winners include Oncothyreon, ImmunoGen and Celldex Therapeutics, while Puma, Clovis and Bristol-Myers lost ground.

ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival

ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival

The CTI Bio drug pacritinib is mostly effective for a small percentage of myelofibrosis patients with dangerously low platelet counts, according to new data from a phase III study.

Cell Therapeutics (CTIC) Strong On High Relative Volume Today

Cell Therapeutics (CTIC) Strong On High Relative Volume Today

Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a strong on high relative volume candidate

First Week of July 17th Options Trading For CTI BioPharma (CTIC)

First Week of July 17th Options Trading For CTI BioPharma (CTIC)

Investors in CTI BioPharma Corp saw new options begin trading this week, for the July 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new July 17th contracts and identified one put and one call contract of particular interest.

Baxter Boosts Oncology Pipeline With $900M Cross-Border Deal

Baxter Boosts Oncology Pipeline With $900M Cross-Border Deal

The deal includes Oncaspar, a treatment for Acute Lymphoblastic Leukemia.

Short Interest In CTI BioPharma Expands By 10.2%

Short Interest In CTI BioPharma Expands By 10.2%

The most recent short interest data has been released by the NASDAQ for the 04/30/2015 settlement date, which shows a 1,837,341 share increase in total short interest for CTI BioPharma Corp , to 19,945,041, an increase of 10.15% since 04/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting CTIC Put And Call Options For December 18th

Interesting CTIC Put And Call Options For December 18th

Investors in CTI BioPharma Corp saw new options begin trading this week, for the December 18th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Short Interest Moves 59.2% Higher For CTIC

Short Interest Moves 59.2% Higher For CTIC

The most recent short interest data has been released by the NASDAQ for the 03/31/2015 settlement date, which shows a 6,825,865 share increase in total short interest for CTI BioPharma Corp , to 18,352,923, an increase of 59.22% since 03/13/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of May 15th Options Trading For CTI BioPharma (CTIC)

First Week of May 15th Options Trading For CTI BioPharma (CTIC)

Investors in CTI BioPharma Corp saw new options begin trading this week, for the May 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new May 15th contracts and identified the following call contract of particular interest.

Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene

Biotech Stock Mailbag: Breaking the Feuerstein-Ratain Rule; Medical Conferences; Celgene

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

3 Biotech Stocks on Traders' Radars: Technical Charts

3 Biotech Stocks on Traders' Radars: Technical Charts

Here's how to trade some of the most active biotech stocks on the market today.

CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing

CTI BioPharma Discloses More Data on Myelofibrosis Drug in SEC Filing

The cross-trial comparison between CTI BioPharma's pacritinib and Incyte's Jakafi looks worse than expected.

4 Big Stocks on Traders' Radars: Rite Aid, BlackBerry and More

4 Big Stocks on Traders' Radars: Rite Aid, BlackBerry and More

Here's how to trade some of the most active stocks on the market right now.

CTI Biopharma (CTIC) Stock Gains Today on Positive Myelofibrosis Study Results

CTI Biopharma (CTIC) Stock Gains Today on Positive Myelofibrosis Study Results

CTI Biopharma (CTIC) shares are rising after the company announced positive results from its phase III study of myelofibrosis drug treatment pacritinib.

CTI Biopharma Posts Positive Myelofibrosis Study Results

CTI Biopharma Posts Positive Myelofibrosis Study Results

CTI Biopharma's experimental drug pacritinib significantly reduced the spleen size in patients with myelofibrosis compared to patients treated with best alternative care.

Heavy Volume And Pre-Market Movement For Cell Therapeutics (CTIC)

Heavy Volume And Pre-Market Movement For Cell Therapeutics (CTIC)

Trade-Ideas LLC identified Cell Therapeutics (CTIC) as a pre-market mover with heavy volume candidate

Insider Trading Alert - CTIC, CRM And ROK Traded By Insiders

Insider Trading Alert - CTIC, CRM And ROK Traded By Insiders

Stocks with insider trader activity include CTIC, CRM and ROK

Insider Trading Alert - MCBC, CTIC And DIS Traded By Insiders

Insider Trading Alert - MCBC, CTIC And DIS Traded By Insiders

Stocks with insider trader activity include MCBC, CTIC and DIS

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

Could This Biotech Stock Be First to Break Feuerstein-Ratain Rule?

The F-R Rule has a perfect record predicting the failure of phase III cancer trials when the company running the trial has a market cap of $300 million or less.

TheStreet Quant Rating: D (Sell)